These were the worst performing ASX 200 shares last week

Avita Therapeutics Inc (ASX:AVH) and Ramelius Resources Limited (ASX:RMS) shares were among the worst performers on the ASX 200 last week…
The post These were the worst performing ASX 200 shares last week appeared first on Motley Fool Australia. –

beaten down shares

The S&P/ASX 200 Index (ASX: XJO) was on form last week thanks largely to strong gains in the banking sector. The benchmark index rose 1.7% higher over the five days to end at 5,964.9 points.

Unfortunately, not all shares on the index pushed higher last week. Here’s why these were the worst performers on the ASX 200 over the period:

Ramelius Resources Limited (ASX: RMS)

The Ramelius share price was the worst performer on the ASX 200 last week with a sizeable 17% decline. Investors were selling the gold miners last week after the spot gold price crashed to a two-month low. A strengthening U.S. dollar and stimulus concerns weighed on the price of the precious metal. For the same reason, fellow gold miners Gold Road Resources Ltd (ASX: GOR) and St Barbara Ltd (ASX: SBM) were the next worst performers with declines of 13% and 12.8%.

Virgin Money UK (ASX: VUK)

The Virgin Money UK share price wasn’t far behind with a disappointing 12.4% decline over the five days. The catalyst for this was an escalation in coronavirus cases in the UK which prompted the government to warn that lockdowns could be coming again. Things have got so bad in recent weeks that health officials warned that there could be upwards of 50,000 new cases per day next month if things aren’t brought under control.

Avita Therapeutics Inc (ASX: AVH)

The Avita share price was out of form last week and tumbled 11.7% lower. This may have been triggered by news that its CEO, Dr Michael Perry, had sold shares in the company. Dr Perry sold 9,000 of its US stock for an average of US$27.41 per share. This equates to a total consideration of approximately US$246,690.

Unibail-Rodamco-Westfield (ASX: URW)

The Unibail-Rodamco-Westfield share price was the next worst (non-gold miner) ASX 200 share with a decline of 8.2% last week. This shopping centre operator’s decline also appears to be related to the escalating coronavirus cases in the UK and Europe. Potential lockdowns and social distancing initiatives are likely to put pressure on its shopping centres. In addition to this, last week Macquarie retained its neutral rating but cut its price target on the company’s shares by 28% to $2.96.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post These were the worst performing ASX 200 shares last week appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!